Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 8 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The sales forecast was left unchanged because sales are tracking in line with the plan. Operating profit and ordinary profit were revised downward due to higher development costs ahead of the launch of a next-generation cloud-based medical claims processing system for the healthcare business, and higher promotional expenses associated with the expansion of partnership agreements for the “LunaLuna Mirai Support” service on a prefecture-by-prefecture basis. The extraordinary gain of ¥524 million from consumption tax refunds, etc. is expected to be an upward factor for net income attributable to owners of the parent even after taking the corporate tax burden into account.
Extraordinary gain: ¥524 million from “consumption tax refunds, etc.”
| Item | Details |
|---|---|
| Net Sales | ¥31,500 million → ¥31,500 million |
| Operating profit | 3,100～3,500 → ¥2,700 million（△22.9～△12.9） |
| Ordinary income | 3,400～3,800 → ¥3,100 million（△18.4～△8.8） |
| Profit attributable to owners of the parent | 2,560～2,840 → ¥2,680 million（△5.6～+4.7） |
| Net income per share | 44.29～49.33 → 48.25 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 8 May 2026 |
| Previous-period results | Fiscal year ended September 2025: sales of ¥29,910 million, operating profit of ¥2,946 million, ordinary profit of ¥3,027 million, net income attributable to owners of the parent of ¥3,404 million, and net income per share of ¥61.62 |
| Reason for the revision | The sales forecast was left unchanged because sales are tracking in line with the plan. Operating profit and ordinary profit were revised downward due to higher development costs ahead of the launch of a next-generation cloud-based medical claims processing system for the healthcare business, and higher promotional expenses associated with the expansion of partnership agreements for the “LunaLuna Mirai Support” service on a prefecture-by-prefecture basis. The extraordinary gain of ¥524 million from consumption tax refunds, etc. is expected to be an upward factor for net income attributable to owners of the parent even after taking the corporate tax burden into account. |
| Details and amount of extraordinary loss | Extraordinary gain: ¥524 million from “consumption tax refunds, etc.” |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The sales forecast was left unchanged because sales are tracking in line with the plan. Operating profit and ordinary profit were revised downward because development costs are expected to increase ahead of the launch of a next-generation cloud-based medical claims processing system for the healthcare business, while promotional expenses are expected to rise as partnership agreements for the “LunaLuna Mirai Support” service expand on a prefecture-by-prefecture basis. Net income attributable to owners of the parent is expected to benefit from the recognition of an extraordinary gain of ¥524 million from consumption tax refunds, etc., which will be an upward factor even after taking the corporate tax burden into account.